10 november 2022: Bron: Evid Based Complement Alternat Med. 2022; 2022: 1375724.
Wanneer borstkankerpatiënten met triple negatieve borstkanker een neoadjuvante chemotherapie combineren met na de complete mastectomie / operatie 8 weken TCM - Traditionele Chinese Medicijnen / Kruiden in de vorm van de zogeheten Zhengyuan Capsule dan bereiken veel meer patiënten een complete remissie (40 vs 70 procent), verminderen de bijwerkingen met meer dan de helft (35 vs 75 procent) (P < 0.05) waardoor ook veel betere kwaliteit van leven werd gezien en ervaren. En blijkt de kans op een recidief op 3-jaarsmeting stukken minder (30,00% versus 10,00%, P <0,05). Dit in vergelijking met alleen neoadjuvante chemotherapie met cyclophosphamide 600 mg/m2 plus doxorubicin 60 mg/m2 plus docetaxel 100 mg/m2 regiem.
De studie analyseerde totaal 120 patiënten met triple negatieve borstkanker gerandomiseerd ingedeeld in 2 groepen van ieder 60 patiënten. De Zhengyuan Capsule werd 8 weken lang ingenomen door 60 patiénten na de operatie. De controlegroep kreeg alleen de chemotherapie.
Het volledige studierapport is gratis in te zien of te downloeden al vind ik de Engelse vertaling van het Chinees beetje verwarrend want ze spreken over neoadjuvante chemotherapie en daarna schrijven ze dat de chemo werd gegeven na de operatie. Maar gezien het standaard protocol dat geldt van neoadjuvante chemotherapie voor deze groep van patiënten en hoe het verdere verloop wordt beschreven ga ik uit van neoadjuvante chemotherapie.
Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
- PMID: 35656462
- PMCID: PMC9152350
- DOI: 10.1155/2022/1375724
Abstract
Objective: To study the clinical effect of Zhengyuan capsule combined with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer (TNBC).
Methods: From September 2014 to September 2017, 120 TNBC patients who underwent radical mastectomy in our hospital were randomly divided into control group (n = 60) and observation group (n = 60). The short-term curative effect, the incidence of toxicity and side effects, and the score of quality of life of the patients were compared. Both recurrence and metastasis rates were also analyzed.
Results: The combined treatment of Zhengyuan capsule with neoadjuvant chemotherapy significantly improved the objective remission rate (70.00% in the observation group versus 40.00% in the control group) (P < 0.05). Moreover, this combined treatment significantly decreased the total incidence of side effects (35.00% versus 75.00%). Accordingly, the score of quality of life was also increased in patients treated with Zhengyuan capsule plus neoadjuvant chemotherapy (P < 0.05). Furthermore, supplementation of Zhengyuan capsule can significantly suppress both the recurrence and metastasis rate of TNBC in patients treated with neoadjuvant chemotherapy after radical mastectomy in following 3 years (30.00% versus 10.00%, P < 0.05).
Conclusion: Zhengyuan capsule effectively improves the short-term curative effect, reduces the side effects of chemotherapy, and improves the quality of life of patients treated with neoadjuvant chemotherapy after radical mastectomy. More importantly, this combined treatment can also reduce the long-term recurrence and metastasis of TNBC.
Copyright © 2022 Xiaoyu Zhang et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Similar articles
-
Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer.World J Clin Cases. 2022 Apr 26;10(12):3698-3708. doi: 10.12998/wjcc.v10.i12.3698.PMID: 35647172 Free PMC article.
-
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.PMID: 29501363 Clinical Trial.
-
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Epub 2011 Feb 3.PMID: 21290263 Review.
-
[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].Zhonghua Yi Xue Za Zhi. 2016 Mar 29;96(12):940-3. doi: 10.3760/cma.j.issn.0376-2491.2016.12.007.PMID: 27045718 Chinese.
-
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.Cancer J. 2021 Jan-Feb 01;27(1):41-49. doi: 10.1097/PPO.0000000000000498.PMID: 33475292 Review.
References
- Guan J., Luo Z., Xiao Z., Lin L. Study on the efficacy and mechanism of Zhengyuan capsule in the prevention and treatment of chemotherapy-related fatigue in nude mice with lung adenocarcinoma A549 transplanted tumor. Journal of Guangzhou University of Traditional Chinese Medicine . 2020;37(5):929–937.
- Qi S. Clinical study of Zhengyuan capsule combined with VDPAP regimen in the treatment of 25 children with acute lymphoblastic leukemia. Medical Tribune Magazine . 2019;40(4):139–140.
- Tian X., Wang Y., Cui Y., Kang X., Kou W., Hui M. Z. Effect of Zhengyuan capsule on quality of life of patients with cancer-related fatigue. International Medical and Health Bulletin . 2019;7:1018–1021.
- Tian X. The Effect of Cancer-Related Fatigue and Zhengyuan Capsule on the Quality of Life of Patients with Advanced Malignant Tumor Cancer-Related Fatigue in the Real World . Xinxiang, China: Xinxiang Medical College; 2019.
- Chen M., Jiang Y. Analysis of the efficacy and safety of Zhengyuan capsule combined with methotrexate in the treatment of childhood acute lymphoblastic leukemia. Journal of Practical Cancer . 2018;33(1):166–168.
- Cázares Marinero J. D. J., Lapie E. M., Cavaillès V. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species. Dalton Transactions . 2013;42(43):15489–15501. - PubMed
- Dong L., Wang L., Qiu X., Shen W. Clinical analysis of Zhengyuan capsule combined with Peimenase and chemotherapy in the treatment of childhood acute lymphoblastic leukemia. Journal of Practical Cancer . 2017;32(6):978–981.
- Ridge C. A., Mcerlean A. M., Ginsberg M. S. Epidemiology of Lung Cancer . Heidelberg, Germany: Springer Berlin; 2006. pp. 173–177.
- Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. Journal of Clinical Oncology . 2004;22(19):3860–3867. doi: 10.1200/jco.2004.01.153. - DOI - PubMed
- Guan J. Study on the Efficacy and Mechanism of Zhengyuan Capsule in the Prevention and Treatment of Cancer-Related Fatigue . Guangzhou, China: Guangzhou University of Traditional Chinese Medicine; 2016.
Gerelateerde artikelen
- Zhengyuan-capsule gecombineerd met neoadjuvante chemotherapie voor triple-negatieve borstkanker geeft veel meer complete remissies en de helft minder bijwerkingen
- TCM - Traditionele Chinese medicijnen / kruiden gebruik naast chemo geeft 12 procent minder doden aan gevorderde uitgezaaide borstkanker over 10 jaar geregistreerd.
- Chinese kruiden verbeteren bijna altijd de effecten van chemo en verminderen eigenlijk altijd de bijwerkingen ervan. Klik hier voor artikelen over TCM - Traditionele kruiden. copy 1
Plaats een reactie ...
Reageer op "Zhengyuan-capsule gecombineerd met neoadjuvante chemotherapie voor triple-negatieve borstkanker geeft veel meer complete remissies en de helft minder bijwerkingen"